| Drug General Information |
| Drug ID |
D01UPT
|
| Former ID |
DIB013695
|
| Drug Name |
FA-70
|
| Indication |
Major depressive disorder [ICD9: 296.2, 296.3, 710.0; ICD10:F32, F33, M32]
|
Investigative |
[1]
|
|---|
| Company |
Universitat Autonoma de Barcelona
|
| Structure |
|
Download
2D MOL
3D MOL
|
| Canonical SMILES |
c1(n(c2c(c1)cc(cc2)O)C)CN(CC#CC)C
|
| CAS Number |
CAS 133846-05-6
|
| Target and Pathway |
| Target(s) |
Amine oxidase [flavin-containing] A |
Target Info |
Inhibitor |
[1]
|
|---|
|
BioCyc Pathway
|
Superpathway of tryptophan utilization
|
|
Dopamine degradation
|
|
Putrescine degradation III
|
|
Noradrenaline and adrenaline degradation
|
|
Serotonin degradation
|
|
Superpathway of melatonin degradation
|
|
Melatonin degradation II
|
|
KEGG Pathway
|
Glycine, serine and threonine metabolism
|
|
Arginine and proline metabolism
|
|
Histidine metabolism
|
|
Tyrosine metabolism
|
|
Phenylalanine metabolism
|
|
Tryptophan metabolism
|
|
Drug metabolism - cytochrome P450
|
|
Metabolic pathways
|
|
Serotonergic synapse
|
|
Dopaminergic synapse
|
|
Cocaine addiction
|
|
Amphetamine addiction
|
|
Alcoholism
|
|
NetPath Pathway
|
IL4 Signaling Pathway
|
|
PANTHER Pathway
|
Adrenaline and noradrenaline biosynthesis
|
|
5-Hydroxytryptamine degredation
|
|
Dopamine receptor mediated signaling pathway
|
|
PathWhiz Pathway
|
Histidine Metabolism
|
|
Tyrosine Metabolism
|
|
Glycine and Serine Metabolism
|
|
Reactome
|
Norepinephrine Neurotransmitter Release Cycle
|
|
WikiPathways
|
SIDS Susceptibility Pathways
|
|
Biogenic Amine Synthesis
|
|
Oxidative Stress
|
|
Dopamine metabolism
|
|
Phase 1 - Functionalization of compounds
|
|
Neurotransmitter Release Cycle
|
|
Neurotransmitter Clearance In The Synaptic Cleft
|
|
Serotonin Transporter Activity
|
| References |
| REF 1 | (http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2489). |
|---|
